find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
298
Clinical Trials
Multiple Myeloma
Phase II
Accepting Patients
nct/study# NCT04649359 / C1071003
An Open-Label, Multicenter, Non-Randomized Phase 2 Study Of Pf-06863135 Monotherapy In Participants With Multiple Myeloma Who Are Refractory To At Least One Proteasome Inhibitor, One Immunomodulatory Drug And One Anti-Cd38 Antibody
Learn More
Multiple Myeloma
Phase I
Accepting Patients
nct/study# NCT04398680 / GSK-209627
A Phase I Study to Evaluate the pharmacokinetics and safety of Belantamab Mafodotin Monotherapy in participants with Relapsed or Refractory Multiple Myeloma who have normal and varying degrees of impaired hepatic function (DREAMM 13)
Learn More
Multiple Myeloma
Phase I
Accepting Patients
nct/study# NCT04398745 / GSK-209626
A Phase I Study to Evaluate the Pharmacokinetics and Safety of belantamab mafodotin Monotherapy in Participants with Relapsed and/or Refractory Multiple Myeloma (RRMM) Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)
Learn More
Multiple Myeloma
Phase I
Accepting Patients
nct/study# NCT04436029 / DC11B
Descartes-11 Consolidation Treatment In Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Learn More
Multiple Myeloma
NA
Accepting Patients
nct/study# NCT02911571 / PROMMIS
Prospective Observational Multiple Myeloma Impact Study Prospective Multicenter Study To Measure The Impact Of Mmprofiler On Treatment Intention In Active Multiple Myeloma Patients
Learn More
Multiple Myeloma
Phase 1/2
Active
nct/study# NA / CP-NEXI-002-01
A Phase 1 / 2 Study To Evaluate The Safety And Tolerability Of Adoptively Transferred Autologous T Cells In Patients With Relapsed Refractory Multiple Myeloma
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.